Valeant Pharmaceuticals Intl Inc (VRX) Put Volume Pops After Fraud Accusations

Valeant Pharmaceuticals Intl Inc (VRX) puts are hot after a chilling Citron Research report

Oct 21, 2015 at 11:38 AM
facebook twitter linkedin


Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares are plummeting -- and were temporarily halted -- on a devastating short-seller report. The stock was last seen roughly 24% lower at $111.50, and earlier touched a two-year low of $98.35. Against this backdrop, the stock has landed on the short-sale restricted list, and option bears are blitzing the biotech.

At last check, roughly 65,000 VRX puts have changed hands -- 10 times the average intraday put volume, and nearly twice the number of VRX calls exchanged. The equity's 30-day at-the-money implied volatility has spiked to a fresh 52-week high of 144.70%, more than doubling from yesterday's close.

Most popular thus far is the weekly 10/23 95-strike put, which has garnered a healthy amount of what looks like buy-to-open action. By purchasing the puts at a volume-weighted average price (VWAP) of $3.94, the buyers will make money if VRX sinks beneath $91.06 -- territory not explored since mid-2013 -- by Friday's close, when the options expire. Delta on the put sat at zero yesterday -- when the contract was even deeper out of the money -- but has surged to negative 0.23 today, implying a 23% chance of expiring in the money.

Even before today, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was under fire for its drug pricing. As alluded to earlier, the equity's foray into double-digit territory today was prompted by a report from Citron Research -- "Valeant: Could this be the Pharmaceutical Enron?" -- which accused the company of fraud and a "cover up." 
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners